ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "juvenile idiopathic arthritis (JIA) and treatment"

  • Abstract Number: 2381 • 2018 ACR/ARHP Annual Meeting

    Long-Term Disease Control Among Patients with Juvenile Idiopathic Arthritis Receiving Adalimumab (Humira) Treatment for up to Six Years

    Daniel J Lovell1, Nicola Ruperto2, Andreas Reiff3, Lawrence Jung4, Katerina Jarosova5, Richard Mouy6, Isabelle Koné-Paut7, Olcay Y. Jones8, Veronika Vargova9, Carine Wouters10, Ivan Lagunes Galindo11, Carmen Mak12, Hermine I. Brunner13 and Alberto Martini2, 1Cincinnati Children’s Medical Center and Pediatric Rheumatology Collaborative Study Group Coordinating Center, Cincinnati, OH, 2Gaslini Institute and Pediatric Rheumatology International Trials Organisation, Genoa, Italy, 3Children's Hospital Los Angeles, Los Angeles, CA, 4Children’s National Health Systems, Washington, DC, 5Institute of Rheumatology, Prague, Czech Republic, 6Hôpital Necker-Enfants Malades, Paris, France, 7Bicetre Hospital, APHP, University of Paris Sud, Paris, France, 8Walter Reed National Military Medical Center, Bethesda, MD, 9Faculty Hospital, Kosice, Slovakia, 10University Hospital Gasthuisberg, Leuven, Belgium, 11AbbVie Inc., North Chicago, IL, 12AbbVie, North Chicago, IL, 13Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is a broad term that describes a clinically heterogeneous group of arthritides of unknown cause, which begin before 16 years…
  • Abstract Number: 2282 • 2017 ACR/ARHP Annual Meeting

    The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Interim Report of Baseline Patient Characteristics and Treatment Choices

    Sarah Ringold1, George A. Tomlinson2, Pamela F. Weiss3, Laura E. Schanberg4, Brian M. Feldman5, Mary Ellen Riordan6, Anne C. Dennos7, Vincent Del Gaizo8, Katherine Murphy9 and Yukiko Kimura6, 1Seattle Children's Hospital, Seattle, WA, 2Medicine, Mount Sinai Hospital, Toronto, ON, Canada, 3Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, 4Pediatrics, Duke University Medical Center, Durham, NC, 5Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 6Hackensack University Medical Center, Hackensack, NJ, 7Duke Clinical Research Institute, Durham, NC, 8Parent Partner, Whitehouse Station, NJ, 9Parent Partner, San Francisco, CA

    Background/Purpose: Despite the many available new and effective treatments for polyarticular JIA (P-JIA), there is significant variation in the timing of when biologic medications are…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences